<DOC>
	<DOCNO>NCT00922688</DOCNO>
	<brief_summary>Rationale : It well know insulin resistance occur mediocre intensive surgery , colon cancer surgery . Disturbances insulin action negatively affect postoperative recovery , either prolong capacity body regain normal function , increase metabolic stress risk complication . Several study show focus therapy improve insulin resistance successful . Experimental study show antioxidant agent , like glutamine ( precursor glutathione ) , improve insulin sensitivity . The hypothesis study perioperative parenteral enteral administration glutamine , give dipeptide alanyl-glutamine , reduce prevent postoperative insulin resistance colon cancer patient . The study also focus different route administration , expect differential metabolic effect . Objective : The investigator ' primary objective study whether intravenous enteral administration dipeptide alanyl-glutamine reduce prevent postoperative insulin resistance colon cancer patient . Study design : A double-blinded , placebo control randomise , pilot study Surgery Department Medical Center Alkmaar . Study population : Thirty patient male gender ethnicity , undergo elective open abdominal colon surgery colon cancer , age 18-75 year . Intervention : Patients receive dipeptide alanyl-glutamine intravenously enterally , start 24 hour prior surgery , 24 hour surgery dosage 0.5 g/kg/day , saline ( control group ) , period time . Main study parameters/endpoints : The main study parameter postoperative insulin resistance . Secondary study parameter lipolysis , oxidative stress glucoregulatory hormone . Muscle , liver fat biopsy take study insulin sensitive well inflammatory pathway .</brief_summary>
	<brief_title>Dipeptide Alanyl Glutamine Postoperative Insulin Resistance Colon Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age 18 75 year Colon cancer patient schedule elective open abdominal surgery Capable give informed consent Patients participate another clinical trial Unable receive oral intake Major malabsorption disorder gut Patients diabetes mellitus BMI 30 kg/m2 Use certain medication : thyroid medication , corticosteroid , diuretic medication Known bleeding disorder increase PTT APTT Any medical condition except colon cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Dipeptide Alanyl-Glutamine</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Intracellular signal</keyword>
	<keyword>Antioxidant/oxidant parameter</keyword>
	<keyword>Lipolysis</keyword>
	<keyword>Inflammatory response liver</keyword>
</DOC>